Glucose‐dependent insulinotropic polypeptide receptor antagonist treatment causes a reduction in weight gain in ovariectomised high fat diet‐fed mice-Reference-Cited by-同舟云学术

Glucose‐dependent insulinotropic polypeptide receptor antagonist treatment causes a reduction in weight gain in ovariectomised high fat diet‐fed mice

Published:2022-07-06 Issue:18 Volume:179 Page:4486-4499
ISSN:0007-1188
Container-title:British Journal of Pharmacology
language:en
Short-container-title:British J Pharmacology

Author:

Boer Geke Aline¹²^ORCID,Hunt Jenna Elizabeth¹²,Gabe Maria Buur Nordskov²,Windeløv Johanne Agerlin¹²,Sparre‐Ulrich Alexander Hovard³,Hartmann Bolette¹²,Holst Jens Juul¹²,Rosenkilde Mette Marie²^ORCID

Affiliation:

1. Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark

2. Department of Biomedical Sciences, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark

3. Antag Therapeutics ApS Copenhagen Denmark

Funder

A.P. Møller og Hustru Chastine Mc-Kinney Møllers Fond til almene Formaal

Novo Nordisk Fonden

Publisher

Wiley

Subject

Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bph.15894

Reference63 articles.

1. Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake

2. THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors

3. The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor

4. Glucose-Dependent Insulinotropic Polypeptide May Enhance Fatty Acid Re-esterification in Subcutaneous Abdominal Adipose Tissue in Lean Humans

5. Tirzepatide: a new low for bodyweight and blood glucose

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. GIP-derived GIP receptor antagonists – a review of their role in GIP receptor pharmacology;Peptides;2024-07

2. Duodenal enteroendocrine cells and GIP as treatment targets for obesity and type 2 diabetes;Peptides;2024-04

3. The Role of GLP-1, GIP, MCP-1 and IGFBP-7 Biomarkers in the Development of Metabolic Disorders: A Review and Predictive Analysis in the Context of Diabetes and Obesity;Biomedicines;2024-01-11

4. Recent clinical and pharmacological advancements of incretin-based therapy and the effects of incretin on physiology;Journal of Diabetology;2024-01

5. Enteroendocrine cells and gut hormones as potential targets in the crossroad of the gut-kidney axis communication;Frontiers in Pharmacology;2023-10-19